Accurate calculation of prostate-specific antigen doubling time can be crucial for prostate cancer treatment decisions but is ...
Aptose Biosciences (APTO) announced that the Cohort Safety Review Committee – CSRC – monitoring Aptose’s Phase 1/2 TUSCANY trial of tuspetinib ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback